Table 2.
Percentage changes of hsCRP and LDL-C upon treatments with statins, ezetimibe and bempedoic acid.
| Clinical study | hsCRP (mg/L) |
LDL-C (mg/dL) |
|||||
|---|---|---|---|---|---|---|---|
| pre | post | Δ | pre | post | Δ | ||
| Statins | |||||||
| Pravastatin [247,248] | CARE | 2.3 | 1.9 | −17.4 % vs baseline | 139.2 | 98.0 | −32 % vs baseline |
| Pravastatin [249] | PRINCE | 2.4 | 2.0 | −16.6 % vs baseline | 142.9 | 97.5 | −31.8 % vs baseline |
| Lovastatin [250] | AFCAPS/TexCAPS | 1.6 | 1.3 | −14.8 % vs baseline | 156.0 | 115.0 | −27 % vs baseline |
| Atorvastatin [251,252] | MIRACL | 11.5 | 2.9 | −75.0 % vs placebo | 135.0 | 72.0 | −40 % vs placebo |
| Pravastatin [253] | REVERSAL | 3.0 | 2.9 | −5.2 % vs baseline | 150.2 | 110.4 | −25.2 % vs baseline |
| Atorvastatin [253] | REVERSAL | 3.0 | 1.8 | −36.4 % vs baseline | 150.2 | 78.9 | −46.3 % vs baseline |
| Pravastatin [80,254] | PROVE IT–TIMI 22 | 11.9 | 2.1 | −82.4 % vs baseline | 106.0 | 95.0 | −10.4 % vs baseline |
| Atorvastatin [80,254] | PROVE IT–TIMI 22 | 12.2 | 1.3 | −89.3 % vs baseline | 106.0 | 62.0 | −41.5 % vs baseline |
| Simvastatin [255] | A-to-Z Trial | 2.01 | 0.17 | −91.5 % vs baseline | 112.0 | 62.0 | −44.6 % vs baseline |
| Rosuvastatin [83] | JUPITER | 4.2 | 2.2 | −47.6 % vs baseline | 108.0 | 55.0 | −49.1 % vs baseline |
| Simvastatin [256] | Heart Protection Study | 3.07 | 2.24 | −27 % vs baseline | 127.9 | 95.9 | −25 % vs baseline |
| Atorvastatin [257] | ASCOT | 2.4 | 1.8 | −25.8 % vs baseline | 136.8 | 85.6 | −38.7 % vs baseline |
| Atorvastatin [258] | CARDS | 1.3 | 1.2 | −9.8 % vs baseline | 121.0 | 60.0 | −50.4 % vs baseline |
| Ezetimibe | |||||||
| Ezetimibe + atorvastatin [259] | 2.19 | 1.98 | −10 % vs atorvastatin | 101.8 | 89.5 | −12.1 % vs atorvastatin | |
| Ezetimibe + rosuvastatin [260] | EXPLORER | 1.7 | 1.2 | −17.8 % vs rosuvastatin | 81.5 | 56.9 | −30.2 % vs rosuvastatin |
| Ezetimibe + Simvastatin [90] | SHARP | 1.1 | 0.99 | −21 % vs placebo | 106.0 | 68.9 | −35 % vs placebo |
| Ezetimibe + Simvastatin [89] | IMPROVE-IT | 1.9 | 1.6 | −14 % vs simvastatin | 67.7 | 49.9 | −20 % vs simvastatin |
| Bempedoic acid | |||||||
| Bempedoic acid [93] | CLEAR Tranquility* | 2.21 | 1.35 | −32.5 % vs baseline | 129.8 | 96.2 | −23.5 % vs baseline |
| Bempedoic acid [94] | CLEAR Harmony*** | 1.49 | 1.25 | −14.4 % vs baseline | 103.6 | 88.9 | −12.6 % vs baseline |
| Bempedoic acid [95] | CLEAR Wisdom** | 1.61 | – | −24.1 % vs baseline | 119.4 | 99.7 | −12.1 % vs baseline |
| Bempedoic acid [96] | CLER Serenity** | 2.92 | 2.47 | −25.1 % vs baseline | 158.5 | 121.5 | −21.2 % vs baseline |
| Bempedoic acid plus ezetimibe* [97] | 3.1 | – | −35.1 % vs baseline | 154 | – | −36.2 % vs baseline | |
hsCRP, high-sensitivity c-reactive protein; LDL-C, low-density lipoprotein cholesterol; -, not available. Adapted from [76] with permission of Taylor & Francis.
*
Post = 12 weeks.
**
Post = 24 weeks.
***
Post = 52 weeks.